Mode
Text Size
Log in / Sign up

Repetitive transcranial magnetic stimulation cuts neuropathic pain intensity with large effect in meta-analysisMagnetic brain stimulation eases nerve pain, review finds

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider rTMS for neuropathic pain based on significant pain reduction, but note high heterogeneity and limited long-term data.

This is a meta-analysis of randomized trials evaluating repetitive transcranial magnetic stimulation (rTMS) for peripheral neuropathic pain. The analysis pooled data from 435 patients and compared rTMS to sham stimulation.

The authors found that rTMS significantly improved pain intensity, with a standardized mean difference of -1.11 (95% CI: -1.72 to -0.49; p = 0.0004). A 30% reduction in pain was achieved with a relative risk of 3.31 (95% CI: 0.98 to 11.20; p = 0.05). Sleep quality and Patient Global Impression of Change were not statistically significant.

The authors noted high heterogeneity and limited long-term data as key limitations. Safety analysis showed no significant increase in adverse events such as headache (RR = 1.32, p = 0.1), dizziness, pain at the stimulation site, sleep disturbances, or cognitive complaints.

The findings support the clinical utility of rTMS for neuropathic pain, but the evidence is limited by heterogeneity and lack of long-term follow-up. Practice relevance is restrained pending more robust data.

Living with nerve pain in your hands or feet can make every day a struggle. A new review of studies looked at a treatment called repetitive transcranial magnetic stimulation, or rTMS, which uses magnetic pulses to target brain areas involved in pain.

The review combined results from patients with peripheral neuropathic pain. It found that rTMS significantly improved pain intensity compared to a sham, or fake, treatment. About three times as many people saw their pain drop by at least 30 percent. However, the review did not find significant improvements in sleep quality or in how patients globally felt about their change.

The analysis included 435 patients. Safety was a key focus, and the review found no significant increase in side effects like headaches, dizziness, or pain at the stimulation site. There were no major safety concerns reported.

The review notes some limitations, including high variability between the studies and limited data on long-term effects. While the findings support the clinical utility of rTMS for nerve pain, more research is needed to understand its lasting impact.

What this means for you:
Magnetic brain stimulation may cut nerve pain intensity, but long-term effects are still unclear.

Study Details

Study typeMeta analysis
Sample sizen = 435
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Peripheral neuropathic pain (PNP) results from damage to peripheral nerves, leading to intractable or exaggerated pain. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive therapeutic method that modulates cortical neuronal activity and can promote endogenous opioid release, with a potential analgesic effect. This meta-analysis evaluates the efficacy and safety of rTMS use in PNP patients. METHODS: We systematically searched PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating rTMS in PNP. The primary outcome was pain intensity. Statistical analysis was performed using Review Manager version 5.4.1. Risk of bias was assessed using the Cochrane RoB 2 tool, and a random-effects model was used to compute pooled estimates, expressed as standardized mean differences (SMD), mean differences (MD), and risk ratios (RR) with 95% confidence intervals (CI). RESULTS: Nine studies with 435 patients were included. rTMS significantly improved pain intensity (SMD = -1.11, 95% CI: [-1.72, -0.49]; p = 0.0004) and achieved a 30% reduction in pain (RR = 3.31, 95% CI: [0.98, 11.20]; p = 0.05). Improvements in sleep quality (SMD = -1.02, p = 0.26) and Patient Global Impression of Change were not statistically significant (RR = 1.70, p = 0.13). Safety analysis showed no significant increase in adverse events such as headache (RR = 1.32, p = 0.1), dizziness, pain at the stimulation site, sleep disturbances, or cognitive complaints. CONCLUSION: rTMS significantly reduces pain in PNP patients without major safety concerns. While findings support its clinical utility, high heterogeneity and limited long-term data suggest further standardized trials are warranted. PROSPERO REGISTRATION: CRD42024628350.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.